aHUS Canada is pleased to share some great news from Australia today – Alexion and the Australian government have come to an agreement that will see Soliris provided to aHUS patients. Unfortunately, according to the aHUS Patient Support Group of Australia (aPSGA) and local reports, it still appears as though the funding conditions/criteria are somewhat limited, in that the government will determine how long a patient should stay on therapy. The aPSGA and the manufacturer argue that physicians should be the ones to decide if a patient stays on or goes off therapy. Still, the aPSGA has still reacted favourably to the agreement, which will allow Australians with aHUS to begin treatment and potentially save lives right away.
aHUS Canada will continue to keep the Canadian aHUS community updated with any news on this agreement.
To read the aPSGA’s full press release, please click here.